Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRL017
MIFTS: 50

Prolymphocytic Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Prolymphocytic Leukemia

About this section

MalaCards integrated aliases for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia 12 76 15 73
Leukemia, Prolymphocytic 44
Leukemia Prolymphocytic 55

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1039
MeSH 44 D015463
NCIt 50 C3181
UMLS 73 C0023486
Sources

Summaries for Prolymphocytic Leukemia

About this section
MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to t-cell prolymphocytic leukemia and b cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Epstein-Barr virus infection. The drugs Ketamine and Cefepime have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are cellular and hematopoietic system

Wikipedia : 76 Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Sources

Related Diseases for Prolymphocytic Leukemia

About this section

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 t-cell prolymphocytic leukemia 33.9 ATM MTCP1 MYC TCL1A
2 b cell prolymphocytic leukemia 30.3 CD19 CD38 CD5 FCER2 MYC ZAP70
3 hairy cell leukemia 30.1 ADA CCND1 CD5
4 lymphoma 30.0 ATM CCND1 MYC TCL1A
5 richter's syndrome 29.3 ATM CD38 CD5 MYC
6 anterior scleritis 29.0 CD19 CD5
7 b-cell lymphomas 28.3 CCND1 CD5 FCER2 MYC TCL1A
8 mantle cell lymphoma 28.1 ATM CCND1 CD19 CD5 MYC
9 leukemia, chronic lymphocytic 25.2 ABCB4 ATM CCND1 CD19 CD38 CD5
10 splenic manifestation of prolymphocytic leukemia 12.1
11 leukemia 11.0
12 primary effusion lymphoma 10.5 MYC TCL1A
13 adult lymphoma 10.5 CD5 MYC
14 leukemia, chronic lymphocytic 2 10.4
15 leukemia, b-cell, chronic 10.4
16 synchronous bilateral breast carcinoma 10.4 ATM CCND1
17 chromosome 13q14 deletion syndrome 10.3 CD38 ZAP70
18 plasmablastic lymphoma 10.3 CD38 MYC
19 hemimegalencephaly 10.3 CCND1 MYC
20 lymphatic system cancer 10.2 CD5 MYC
21 cd45 deficiency 10.2 CD5 ZAP70
22 t-cell leukemia 10.1
23 ataxia-telangiectasia 10.0
24 hematopoietic stem cell transplantation 10.0
25 large granular lymphocyte leukemia 10.0
26 kaposi sarcoma 9.9
27 graft-versus-host disease 9.9
28 autoimmune lymphoproliferative syndrome, type v 9.9
29 diffuse large b-cell lymphoma 9.9
30 t-cell large granular lymphocyte leukemia 9.9
31 sarcoma 9.9
32 meningitis 9.9
33 type i 9.9
34 bladder lymphoma 9.9 CD19 CD5
35 chronic leukemia 9.9 ABCB4 CCND1
36 colon lymphoma 9.9 CD19 CD5
37 invasive malignant thymoma 9.8 CD19 CD38
38 b-cell growth factor 9.8
39 breast cancer 9.8
40 prostate cancer 9.8
41 anemia, autoimmune hemolytic 9.8
42 nijmegen breakage syndrome 9.8
43 myocardial infarction 9.8
44 gastric cancer 9.8
45 infantile liver failure syndrome 1 9.8
46 acute leukemia 9.8
47 acute liver failure 9.8
48 adult t-cell leukemia 9.8
49 hemolytic anemia 9.8
50 peripheral t-cell lymphoma 9.8

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:



Diseases related to Prolymphocytic Leukemia
Sources

Symptoms & Phenotypes for Prolymphocytic Leukemia

About this section

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 ABCB4 ADA ATM CCND1 CD19 CD38
2 hematopoietic system MP:0005397 10.02 ABCB4 ADA ATM CCND1 CD19 CD38
3 immune system MP:0005387 9.96 CD19 CD38 CD5 FCER2 MYC ZAP70
4 endocrine/exocrine gland MP:0005379 9.91 ABCB4 ADA ATM CCND1 CD38 MYC
5 digestive/alimentary MP:0005381 9.88 ABCB4 ADA CCND1 CD19 FCER2 MYC
6 integument MP:0010771 9.63 ATM CCND1 CD19 CD5 MYC ZAP70
7 neoplasm MP:0002006 9.35 CCND1 CD19 MYC ABCB4 ATM
8 normal MP:0002873 9.1 MYC ZAP70 ADA CCND1 CD19 CD5
Sources

Drugs & Therapeutics for Prolymphocytic Leukemia

About this section

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 269)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
3
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
4
Ofloxacin Approved Phase 3 82419-36-1 4583
5
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
6
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
8
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
9
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
11
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
12
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
15
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
16
Iron Approved Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Dalteparin Approved Phase 3 9005-49-6
19
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
20
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
22
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
23
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
24
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
25
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
26
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
27
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
28
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
29
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
30 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
31 Analgesics Phase 3,Phase 2,Not Applicable
32 Anesthetics Phase 3
33 Anesthetics, Dissociative Phase 3
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
37 Excitatory Amino Acid Antagonists Phase 3
38 Excitatory Amino Acids Phase 3
39 Neurotransmitter Agents Phase 3,Not Applicable
40 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Cephalosporins Phase 3,Phase 1
44 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Not Applicable
45 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
46 Renal Agents Phase 3,Phase 1,Phase 2
47 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
50 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
4 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
7 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
8 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
11 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
12 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
13 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
14 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
15 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
16 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
17 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
18 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
19 Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
20 Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) Completed NCT00464633 Phase 2 alvocidib
21 Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL Completed NCT00452374 Phase 1, Phase 2 Cytarabine;Fludarabine;Oxaliplatin;Rituximab
22 Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias Completed NCT00472849 Phase 1, Phase 2 Oxaliplatin;Fludarabine;Cytarabine;Rituximab;Pegfilgrastim
23 Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma Completed NCT00006252 Phase 2 fludarabine phosphate;Cyclophosphamide;G-CSF
24 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
25 Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) Completed NCT00005626 Phase 2 Irinotecan
26 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
27 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
28 Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
29 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Completed NCT00364286 Phase 2 Dasatinib (BMS-354825)
30 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Completed NCT01244906 Phase 2
31 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
32 Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Completed NCT00782379 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
33 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
34 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
35 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
36 Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma Completed NCT00278161 Phase 2 cyclophosphamide
37 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
38 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
39 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
40 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
41 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
42 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
43 Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed NCT00026351 Phase 2 pentostatin
44 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
45 Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Completed NCT00001637 Phase 2
46 Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients Completed NCT00410163 Phase 2 Ofatumumab 500mg;Ofatumumab 1000mg;Fludarabine;Cyclophosphamide
47 Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT01191190 Phase 2 Ofatumumab/HDMP
48 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Recruiting NCT03314974 Phase 2
49 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
50 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Sources

Genetic Tests for Prolymphocytic Leukemia

About this section
Sources

Anatomical Context for Prolymphocytic Leukemia

About this section

MalaCards organs/tissues related to Prolymphocytic Leukemia:

41
T Cells, B Cells, Bone, Bone Marrow, Liver, Kidney, Myeloid
Sources

Publications for Prolymphocytic Leukemia

About this section

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 340)
# Title Authors Year
1
T-cell prolymphocytic leukemia negative for surface CD3 and CD45. ( 29976781 )
2018
2
Exploring the molecular pathogenesis associated with T-cell prolymphocytic leukemia based on a comprehensive bioinformatics analysis. ( 29928415 )
2018
3
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. ( 29483097 )
2018
4
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia. ( 29352181 )
2018
5
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. ( 29407180 )
2018
6
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 28377595 )
2017
7
Risk of second cancers in survivors of prolymphocytic leukemia: a SEER data analysis. ( 27924652 )
2017
8
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. ( 28194886 )
2017
9
The distinctive cytological features of T-cell prolymphocytic leukemia. ( 28120343 )
2017
10
Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion. ( 28819574 )
2017
11
A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia. ( 28435655 )
2017
12
T-cell Prolymphocytic Leukemia. ( 28340878 )
2017
13
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. ( 28972014 )
2017
14
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
15
Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma. ( 29199492 )
2017
16
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
17
Advances in the understanding and management of T-cell prolymphocytic leukemia. ( 29262669 )
2017
18
Modified Hyper-CVAD Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation Successfully Treated Synchronous T-Cell Prolymphocytic Leukemia and Gastric Cancer in a 68-Year-Old Female. ( 28824253 )
2017
19
T-cell prolymphocytic leukemia and tuberculosis: a puzzling association. ( 28878921 )
2017
20
Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. ( 28695755 )
2017
21
TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. ( 28232160 )
2017
22
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). ( 28379307 )
2017
23
T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib). ( 29296924 )
2017
24
Broken heart by T-prolymphocytic leukemia. ( 28775161 )
2017
25
Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment. ( 28324286 )
2017
26
PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP. ( 27168399 )
2016
27
Brentuximab Vedotin Therapy for Cutaneous Lesions in T-Prolymphocytic Leukemia: A Case Report. ( 27757215 )
2016
28
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
29
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
30
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2016
31
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 27941777 )
2016
32
A I^/I' T-cell Receptor Prolymphocytic Leukemia and CD4-/CD8- Double-negative Immunophenotype in a Pediatric Patient. ( 25757027 )
2015
33
T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine. ( 26853400 )
2015
34
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL). ( 25888568 )
2015
35
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
36
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
37
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
38
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AA Single-Center Experience. ( 26422251 )
2015
39
Management of prolymphocytic leukemia. ( 26637744 )
2015
40
Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia. ( 26379148 )
2015
41
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
42
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
43
Auer Rod-Like Inclusions in Prolymphocytic Leukemia. ( 26299084 )
2015
44
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015
45
Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. ( 26292711 )
2015
46
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more. ( 26293613 )
2015
47
Encephalitozoon hellem in a patient with CD4(+) T-cell prolymphocytic leukemia: case report and genomic identification. ( 26299583 )
2015
48
A T-cell prolymphocytic leukemia case with central nervous system involvement. ( 26550397 )
2015
49
Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia. ( 25068103 )
2014
50
Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission. ( 24470149 )
2014
Sources

Variations for Prolymphocytic Leukemia

About this section
Sources

Expression for Prolymphocytic Leukemia

About this section
Search GEO for disease gene expression data for Prolymphocytic Leukemia.
Sources

Pathways for Prolymphocytic Leukemia

About this section

Pathways related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.46 ATM CCND1 CD19 MTCP1 MYC TCL1A
2
Epstein-Barr virus infection 37
12.01 CD19 CD38 FCER2 MYC
3
Cellular senescence (KEGG) 37
11.93 ATM CCND1 MYC
4
Integrated Breast Cancer Pathway 1
11.89 ATM CCND1 MYC
5
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.75 CD19 CD38 CD5
6
DNA Damage Response (only ATM dependent) 1
11.73 ATM CCND1 MYC
7
Interleukin-4 and 13 signaling 66
11.71 CCND1 FCER2 MYC
8
C-MYB transcription factor network 1
11.52 ADA CCND1 MYC
9
Regulation of Telomerase 1
11.43 ATM CCND1 MYC
10
miRNAs involved in DNA damage response 1
11.24 ATM CCND1 MYC
11
Hematopoietic cell lineage 37
11.24 CD19 CD38 CD5 FCER2
12
FOXM1 transcription factor network 1
11.15 CCND1 MYC
13
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.14 ATM CCND1 MYC
14
IL-10 Pathway 64
11.12 CCND1 MYC
15
GADD45 Pathway 64
11.07 ATM CCND1
16
Primary immunodeficiency 37
11 ADA CD19 ZAP70
17
PPAR Alpha Pathway 1
10.97 CCND1 MYC
18
TP53 Network 1
Show member pathways
 10.88 ATM MYC
19
B Cell Development Pathways 65
10.65 CD19 CD38 CD5 FCER2
Sources

GO Terms for Prolymphocytic Leukemia

About this section

Cellular components related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.26 CD19 MTCP1 MYC TCL1A
2 external side of plasma membrane GO:0009897 8.92 ADA CD19 CD5 FCER2

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.81 ADA CD38 MYC TCL1A
2 liver regeneration GO:0097421 9.52 CCND1 MYC
3 response to morphine GO:0043278 9.49 ABCB4 ADA
4 positive regulation of T cell differentiation GO:0045582 9.48 ADA ZAP70
5 positive regulation of calcium-mediated signaling GO:0050850 9.46 ADA ZAP70
6 response to hypoxia GO:0001666 9.46 ABCB4 ADA ATM CD38
7 positive regulation of response to DNA damage stimulus GO:2001022 9.43 ATM MYC
8 response to vitamin E GO:0033197 9.4 ADA CCND1
9 positive regulation of alpha-beta T cell differentiation GO:0046638 9.37 ADA ZAP70
10 response to drug GO:0042493 9.35 ABCB4 ADA CCND1 CD38 MYC
11 positive regulation of mitochondrial membrane potential GO:0010918 9.32 MYC TCL1A
12 re-entry into mitotic cell cycle GO:0000320 9.26 CCND1 MYC
13 response to estradiol GO:0032355 8.92 ABCB4 CCND1 CD38 MYC

Molecular functions related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activator activity GO:0043539 8.62 MTCP1 TCL1A
Sources

Sources for Prolymphocytic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....